LEADER Surveillance program results for 2010: An activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 1, 2012, Pages 54-61

  Flamm, Robert K ^a   Farrell, David J ^a   Mendes, Rodrigo E ^a   Ross, James E ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cfr; LEADER; Linezolid; Oxazolidinones; Resistance; Target mutations

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; GENE MUTATION; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; UNIVERSITY HOSPITAL;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; UNITED STATES;

EID: 84865300349     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.012     Document Type: Article

References (42)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 2005, 26:13-21.
2. Arias C.A., Vallejo M., Reyes J., Panesso D., Moreno J., Castaneda E., et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008, 46:892-896.
3. Bonilla H., Huband M.D., Seidel J., Schmidt H., Lescoe M., McCurdy S.P., et al. Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 2010, 51:796-800.
4. Brickner S.J. Oxazolidinone antibacterial agents. Curr Pharm Design 1996, 2:175-194.
5. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk susceptibility tests; approved standard - tenth edition, M02-A10 2009, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard - eighth edition, M07-A8 2009, CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 21st informational supplement (M100-S21) 2011, CLSI, Wayne, PA.
8. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
9. Draghi D.C., Sheehan D.J., Hogan P., Sahm D.F. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005, 49:5024-5032.
10. Draghi D.C., Sheehan D.F., Hogan P., Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 2006, 55:129-133.
11. Farrell D.J., Morrissey I., Bakker S., Buckridge S., Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004, 48:3169-3171.
12. Farrell D.J., Mendes R.E., Ross J.E., Jones R.N. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2009, 65:392-403.
13. Farrell D.J., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from the United States (56 medical centers). Antimicrob Agents Chemother 2011, 55:3684-3690.
14. Ford C.W., Zurenko G.E., Barbachyn M.R. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord 2001, 1:181-199.
15. Fung H.B., Kirschenbaum H.L., Ojofeitimi B.O. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001, 23:356-391.
16. Jones R.N., Johnson D.M., Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996, 40:720-726.
17. Jones R.N., Ross J.E., Fritsche T.R., Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006, 57:279-287.
18. Jones R.N., Fritsche T.R., Sader H.S., Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007, 59:309-317.
19. Jones R.N., Fritsche T.R., Sader H.S., Ross J.E. Zyvox Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007, 59:199-209.
20. Jones R.N., Stilwell M.G., Hogan P.A., Sheehan D.J. Activity of linezolid against 3,251 strains of uncommonly isolated Gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2007, 51:1491-1493.
21. Jones R.N., Ross J.E., Castanheira M., Mendes R.E. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008, 62:416-426.
22. Jones R.N., Kohno S., Ono Y., Ross J.E., Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009, 64:191-201.
23. Jones R.N., Ross J.E., Bell J.M., Utsuki U., Fumiaki I., Kobayashi I., et al. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009, 65:404-413.
24. Locke J.B., Hilgers M., Shaw K.J. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 2009, 53:5275-5278.
25. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009, 53:5265-5274.
26. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
27. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008, 52:2244-2246.
28. Mendes R.E., Deshpande L.M., Farrell D.J., Spanu T., Fadda G., Jones R.N. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010, 65:2329-2335.
29. Pillar C.M., Draghi D.C., Sheehan D.J., Sahm D.F. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis 2008, 60:221-224.
30. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis 2005, 52:53-58.
31. Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 2007, 29:295-301.
32. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 1999, 8:1195-1202.
33. Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
34. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
35. Stevens D.L., Dotter B., Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004, 2:51-59.
36. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007, 64:1506-1514.
37. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
38. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005, 49:3554-3557.
39. Wunderink R.G., Cammarata S.K., Oliphant T.H., Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003, 25:980-992.
40. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
41. Wunderink R.G., Niederman M.S., Kollef M.H., Shorr A.F., Kunkel M.J., Baruch A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
42. Zurenko G.E., Yagi B.H., Schaadt R.D., Allison J.W., Kilburn J.O., Glickman S.E., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40:839-845.